Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04330716Not ApplicableCompleted

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

Role: collaborator

NCT03688204Completed

Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer

Role: lead

NCT04517682Completed

COVID-19 and SARS-CoV-2 Detection in Saliva

Role: lead

NCT02790944Completed

Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

Role: lead

All 4 trials loaded